Market Research Reports and Industry Reports

Cancer Diagnostic Testing World Markets

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this TriMark Publications report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position.

 1. Overview 9
 1.1 Statement of Report 9
 1.2 About this Report 9
 1.3 Scope of the Report 11
 1.4 Objectives 11
 1.5 Methodology 11
 1.6 Executive Summary 13
 
 2. Introduction to Cancer Biology and the Diagnostic Industry 18
 2.1 Cancer 18
 2.1.1 The Disease 18
 2.1.2 Metastasis 19
 2.1.3 Demographics and Statistics of Cancer 19
 2.2 The Drivers of the Biotech and Diagnostics Industry 24
 2.2.1 Technological Innovation 26
 2.2.2 Government Funding 26
 2.3 Outlook for Tumor Markers 26
 
 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 29
 3.1 Market Description 30
 3.2 Clinical Diagnostic Serum-based Cancer Markers 37
 3.3 PSA Testing Market Size 38
 3.4 DNA Markers 39
 3.5 Serum Proteins 39
 3.6 Enzymes 40
 3.7 Occult Blood 40
 3.8 Histology and In Situ Hybridization (ISH) 41
 3.9 Cervical Cytology 41
 3.10 Immunohistochemistry (IHC) 44
 3.11 In Vivo Detection Cancer Products 45
 3.12 Radionuclides and X-Ray Detection Products 45
 3.13 HPV Testing 45
 3.14 Bladder Cancer Testing 48
 3.15 Tumor Assays for Adjuvant Chemotherapy 52
 
 4. Diagnostic Methods for Cancer Detection 66
 4.1 Organ-Specific Tumor Markers 66
 4.1.1 Colon Cancer 66
 4.1.2 Prostate Cancer 77
 4.1.3 Pancreatic Cancer 114
 4.1.4 Breast Cancer 119
 4.1.5 Ovarian Cancer 132
 4.1.6 Cervical Cancer 138
 4.1.7 Lung Cancer 145
 4.1.8 Testicular Cancer 155
 4.1.9 Bladder Cancer 155
 4.1.10 Hepatic Cancer 164
 4.1.11 Stomach Cancer 167
 4.1.12 Malignant Melanoma 168
 4.1.13 Acute Myeloid Leukemia (AML) and Acute Lymphoblastoid Leukemia (ALL) 169
 4.1.14 Lymphoma 170
 4.2 Clinical Laboratory Methods for Measuring Tumor Markers 170
 4.2.1 Abbott Diagnostics AxSYM 170
 4.2.2 Roche Diagnostics Systems 171
 4.2.3 Beckman Coulter Diagnostics Immunoassay Systems 172
 4.2.4 Siemens Healthcare Diagnostics ADVIA Centaur CP Immunoassay System and the ADVIA Centaur XP Immunoassay System 173
 4.2.5 Siemens Healthcare Diagnostics Immulite Systems 173
 4.2.6 Tosoh Bioscience AIA-2000 174
 4.2.7 Thermo Fisher Scientific B.R.A.H.M.S. KRYPTOR 175
 4.2.8 Ortho-Clinical Diagnostics Vitros ECiQ (Johnson and Johnson) 175
 4.2.9 Fujirebio Diagnostics, Inc. 175
 4.2.10 bioMérieux Vidas 176
 4.3 New Technologies for Cancer Diagnostics 177
 4.3.1 New and Improved Immunoassays 177
 4.3.2 IHC Tests 178
 4.3.3 Molecular (DNA and Genomic) Diagnostic Assays 179
 4.3.4 Genomics and Genetic Markers 179
 4.3.5 Proteomics and New Protein Markers 180
 4.3.5.1 Inside the ProteinChip System 181
 4.3.5.2 Rapid Biological Assays on a Chip 181
 4.3.5.3 Proteome Pattern Recognition 181
 4.3.6 New Platform Technologies Including Flow Cytometry 182
 4.3.7 Stem Cell Markers 185
 4.3.8 mAbs 186
 4.3.9 Proteomics and Cancer Antibodies 187
 4.3.10 Pharmacogenomics and Oncology Diagnostics 187
 4.3.11 DNA Microarrays 190
 4.3.12 In Vitro Diagnostic Multi-variate Index Assays (IVDMIA) 192
 4.3.13 Prostate PX Score 192
 4.3.14 Prostate-63 192
 4.3.15 Future Directions 192
 4.4 Clinical Methods for Diagnosis of Cancer 193
 4.4.1 Screening 193
 4.4.2 Sigmoidoscopy 195
 4.4.3 Imaging 195
 4.4.4 Theranostics 197
 
 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 198
 
 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 200
 6.1 Abbott Diagnostics 200
 6.2 Affymetrix, Inc. 201
 6.3 Agendia BV 202
 6.4 Ambrilia Biopharma, Inc. 202
 6.5 ArcticDx, Inc. 203
 6.6 Arcxis Biotechnologies 203
 6.7 Asuragen, Inc. 204
 6.8 Aureon Biosciences, Inc. 204
 6.9 C. R. Bard 204
 6.10 Beckman, Dickinson and Company (BD) Diagnostics-TriPath 205
 6.11 Beckman Coulter (now part of Danaher Corporation) 206
 6.12 Biocode Hycel France S.A. 208
 6.13 BioCurex 209
 6.14 Biomedical Diagnostics 209
 6.15 Biomerica 209
 6.16 bioMérieux 210
 6.17 BioModa, Inc. 210
 6.18 Bruker Daltonics 211
 6.19 Byk Gulden 211
 6.20 Cepheid 211
 6.21 Clarient, Inc. (GE Healthcare) 213
 6.22 CombiMatrix Corporation 213
 6.23 Correlogic Systems, Inc. (Vermillion, Inc.) 214
 6.24 CytoCore (formerly Molecular Diagnostics, Inc.) 214
 6.25 Cytogen Corporation (now EUSA Pharma) 214
 6.26 diaDexus, Inc. 215
 6.27 DiagnoCure, Inc. 216
 6.28 Diagnostic Automation/Cortez Diagnostics, Inc. 217
 6.29 DRG International, Inc. 217
 6.30 Eisai Co., Ltd. 218
 6.31 Enigma Diagnostics Ltd. 219
 6.32 Epigenomics AG 219
 6.33 Exact Sciences Corporation 219
 6.34 Exagen Diagnostics, Inc. 220
 6.35 Exiqon 221
 6.36 Fujirebio Diagnostics, Inc. 221
 6.37 Gene Logic, Inc. 222
 6.38 Gen-Probe, Inc. 222
 6.39 Genomic Health, Inc. 222
 6.40 Geron Corporation 223
 6.41 Hologic, Inc. (formerly Cytyc Corporation) 224
 6.42 Immunicon Corporation (now Veridex, LLC) 228
 6.43 Immunomedics, Inc. 228
 6.44 Ipsogen 229
 6.45 LabCorp 229
 6.46 Urocor, Inc. 230
 6.47 Mitsubishi Kagaku Medical 231
 6.48 Molecular Devices (formerly Arcturus Bioscience, Inc.) 231
 6.49 Myriad Genetics, Inc. 231
 6.50 Northwest Biotherapeutics, Inc. 237
 6.51 ARCA Biopharma 238
 6.52 Oncotech, Inc. 238
 6.53 Oncothyreon, Inc. (formerly Biomira) 238
 6.54 Panacea Pharmaceuticals, Inc. 239
 6.55 Poniard Pharmaceuticals, Inc. 239
 6.56 Polymedco, Inc. 241
 6.57 Princeton BioMeditech Corporation 242
 6.58 QIAGEN NV 243
 6.59 Radient Pharmaceuticals 244
 6.60 Roche (F. Hoffman-La Roche Ltd.) 245
 6.61 Sanko Junyaku Co., Ltd. 246
 6.62 Siemens Heathcare Diagnostics 246
 6.63 Seegene 247
 6.64 Sequenom, Inc. 248
 6.65 SABiosciences Corporation (Qiagen) 248
 6.66 Source MDx 248
 6.67 Targeted Molecular Diagnostics 248
 6.68 Tosoh Corporation (Bioscience division) 249
 6.69 Ventana Medical Systems, Inc. 249
 6.70 Veridex, LLC 249
 6.71 Vermillion, Inc. 249
 6.72 Worldwide Medical Corporation 250
 6.73 Xenomics, Inc. (TrovaGene, Inc.) 250
 
 7. Business Trends in the Industry 251
 7.1 Industry Consolidation 251
 7.2 Breadth of Product Offering and Pricing 251
 7.3 Government Regulation of Medical Devices 252
 7.4 Commercial Opportunities in Cancer Markers 253
 7.5 Moderators of Growth 254
 7.6 Biotechnology Industry Trends 255
 7.7 Pharmaceutical Industry Trends 256
 7.8 Sales and Marketing Strategies for Tumor Marker Tests 259
 7.8.1 North American Market 260
 7.8.2 International Markets 261
 7.8.2.1 Europe 261
 7.8.2.2 Central and South America 261
 7.8.2.3 Asia-Pacific 262
 
 8. Tumor Marker Testing: Important Issues 263
 8.1 Trends in Patient Care and Reimbursement 263
 8.2 Trends in Reimbursement Practice 264
 8.3 Clinical Laboratory Improvement Act (CLIA) 267
 8.4 Unmet Needs in Tumor Markers 268
 
 9. Important New Technology Areas 269
 9.1 Proteins 269
 9.2 DNA Sequencing 270
 9.3 The Human Genome Project (HGP) 271
 9.4 Liquid Phase Chromatography 272
 9.5 Polymerase Chain Reaction (PCR) 273
 9.6 Capillary Electrophoresis 274
 9.7 Proteomics 275
 9.8 Use of Mass Spectrometry (MS) in Sequencing 276
 9.9 High-Throughput Organic Synthesis 281
 
 10. New Cancer Markers in Basic Research 282
 10.1 Genetics of Cancer 282
 10.1.1 Activator Genes (Oncogenes) 282
 10.1.2 Inactivating Genes (Tumor Suppressor Genes) 284
 10.2 DNA Mismatch Repair Genes (MMRs) 286
 10.3 Telomeres 287
 10.4 Diseases 291
 10.4.1 t(15;17) in Acute Promyelocytic Leukemia (APL) 291
 10.4.2 t(12;21) in Acute Lymphoblastic Leukemia (ALL) 291
 10.4.3 Retinoblastoma and Constitutional 13q14 Deletion 291
 10.4.4 Stomach Cancer 291
 10.4.5 Head and Neck Cancer 292
 10.4.6 Breast and Ovarian Cancers 293
 10.4.7 Prostate Cancer 294
 10.4.8 Cervical Cancer: NMPI79 296
 10.4.9 Uterine and Kidney Cancer: MN/CA9 296
 10.4.10 Colon Cancer: Serum Vascular Endothelial Growth factor (VEGF) 297
 10.4.11 Lung Cancer: Ribonucleoprotein A2/B1 and microRNA Markers 297
 10.5 Tumor Markers 297
 10.5.1 Oncology Biomarker Qualification Initiative 297
 10.5.2 CRC: Carcinoembryonic Antigen (CEA) Doubling Time 298
 10.5.3 MUC1, 2, 3 and 4 298
 10.5.4 Cytokeratins 299
 10.5.5 RAK Antigens 299
 10.5.6 Serum Urokinase Receptors 299
 10.5.7 Survivin 299
 10.5.8 Reg-4 Protein 300
 10.5.9 NADPH Oxidases 1 and 2 (NOX1 and NOX2) 300
 10.5.10 Prostate Secretory Protein 94- (PSP94)-Binding Protein 300
 10.5.11 Shc Proteins 301
 10.5.12 Anti-Glycan Antibodies 301
 10.5.13 YKL-40 301
 10.5.14 Alpha-Fetoprotein (AFP)-L3 302
 10.5.15 Transthyretin and Apo Lipoprotein A1 (Apo A1) 302
 10.5.16 A Disintegrin and Metalloproteinase (ADAM) 302
 10.6 Technology 302
 10.6.1 Chips 302
 10.6.2 Ettan DIGE Technology 303
 10.6.3 DNA Methylation Technology 303
 10.7 Disease-Specific Technology 304
 10.7.1 Ovarian Cancer: Bio-Rad’s SELDI-based ProteinChip 304
 10.7.2 Lung Cancer: Labeled Porphyrin Binding 304
 10.7.3 C-MAP, A Cervical Cancer Screening System 304
 10.7.4 Lung Cancer: Pro-Gastrin-Releasing Peptide (ProGRP) 304
 10.7.5 Prostate Cancer: PCA3 304
 10.7.6 Bladder Cancer: ImmunoCyt/uCyt+ 307
 
 11. Market Trends and Forecasts 309
 11.1 Ultrasensitive Cancer Tests 309
 11.2 Mergers and Acquisitions (M&As) of Diagnostic Companies 310
 11.3 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 310
 11.4 Genetic Tests of Hereditary Cancer Risk 311
 11.5 DNA Measurements 311
 11.6 Technical and Practical Issues for Potential New Markers 311
 11.7 Genetic Profiling 313
 11.8 Ploidy 313
 11.9 Advances in Sputum Analysis for Screening and Early Detection of Lung Cancer 314
 11.10 Pharmacogenetic Tests for Cancer 314
 11.11 Worldwide Healthcare Spending 315
 
 Appendix 1: Web Links 317
 Appendix 2: Cancer Information Resources 320
 Appendix 3: Colon Cancer Staging 321
 Appendix 4: Reimbursement for Tumor Marker Testing 323
 Appendix 5: The Pathology of Prostate Cancer 326
 Appendix 6: Government Regulation of Tumor Marker Tests 328
 Appendix 7: The Clinical Laboratory Improvement Act (CLIA) 331
 Appendix 8: Marketers of Occult Blood Diagnostic Test Kits 334


List Of Tables

 Table 2.1: Organ-Specific Medicines in Development for Cancer 20
 Table 2.2: Estimates for the Leading Sites of New Cancer Cases in the U.S. by Gender, 2013 21
 Table 2.3: Estimates for the Leading Sites of Cancer Deaths in the U.S. by Gender, 2013 21
 Table 2.4: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer (Men) 21
 Table 2.5: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer (Women) 22
 Table 2.6: Estimated Age-Standardized Incidence and Mortality Rates Per 100,000 by World Area, 2008 23
 Table 2.7: Cancer-Associated Genes 23
 Table 2.8: Carcinogens in the Workplace 24
 Table 2.9: Private Funding Levels for the Biotechnology Segment, 1995-2012 25
 Table 2.10: Herceptin Worldwide Sales, 2000-2017 27
 Table 2.11: Classes of Drugs Used to Treat Breast Cancer 28
 Table 3.1: Tumor Biomarkers Currently in Common Use 32
 Table 3.2: Global IVD Cancer Tumor Marker Testing Market Segments Growth Rates, 2009-2019 33
 Table 3.3: Worldwide Market Size in Dollar Volume for Tumor Marker Assays Product Market,
 2009-2019 34
 Table 3.4: U.S. Market Size in Dollar Volume for Tumor Marker Assays Product Market, 2009-2019 34
 Table 3.5: Worldwide In Vitro Cancer Tumor Marker Diagnostics Market Size, 2009-2019 35
 Table 3.6: U.S. In Vitro Cancer Tumor Marker Diagnostics Market Size, 2009-2019 35
 Table 3.7: Japanese In Vitro Cancer Tumor Marker Diagnostics Market Size, 2009-2019 36
 Table 3.8: European In Vitro Cancer Tumor Marker Diagnostics Market Size, 2009-2019 36
 Table 3.9: Market Share of Major Competitors in U.S. Cancer Tumor Marker Diagnostics Market 36
 Table 3.10: Major Presence in Cancer Tumor Marker Diagnostics Markets 37
 Table 3.11: Worldwide PSA Sales, 2009-2019 38
 Table 3.12: U.S. PSA Sales, 2009-2019 39
 Table 3.13: Serum Markers Used Clinically 39
 Table 3.14: Drivers of IHC Growth 44
 Table 3.15: Bladder Cancer Testing Efforts in the U.S. and Germany 49
 Table 3.16: Worldwide Bladder Cancer Marker Sales, 2009-2019 51
 Table 3.17: U.S. Bladder Cancer Marker Sales, 2009-2019 51
 Table 3.18: Worldwide NMP22 Sales, 2009-2019 52
 Table 3.19: Breast Cancer Products and Product Opportunities, 2011 60
 Table 3.20: Products in Various Stages of Development for Cancers Other than Breast Cancer 62
 Table 4.1: CRC Stages 68
 Table 4.2: Percentage of Respondents Aged ≥50 Years who Reported Receiving a Fecal Occult Blood Test Within One Year, or a Lower Endoscopy* Within Ten Years, by Age and Sex in the U.S., 2002, 2004,
 2006 and 2008 70
 Table 4.3: Number of Procedures Based on Patients Aged ≥50 Years who Reported Receiving a Fecal Occult Blood Test Within One Year or a Lower Endoscopy* Within Ten Years, by Age and Sex in the U.S., 2008 70
 Table 4.4: Worldwide CEA Sales, 2009-2019 72
 Table 4.5: U.S. CEA Sales, 2009-2019 73
 Table 4.6: Japan CEA Sales, 2009-2019 73
 Table 4.7: Europe CEA Sales, 2009-2019 74
 Table 4.8: Rest of the World CEA Sales, 2009-2019 74
 Table 4.9: Worldwide PSA Sales, 2009-2019 79
 Table 4.10: U.S. PSA Sales, 2009-2019 79
 Table 4.11: Japan PSA Sales, 2009-2019 80
 Table 4.12: Europe PSA Sales, 2009-2019 80
 Table 4.13: Rest of the World PSA Sales, 2009-2019 81
 Table 4.14: Population Statistics of Serum Levels of PSA in Men Over 50 Years of Age 88
 Table 4.15: Cell Doubling Time and Time to Reach PSA Level of 1,000 ng/mL 89
 Table 4.16: Human tissue Kallikreins as Cancer Markers 93
 Table 4.17: New Diagnostic Tests for Prostate Cancer 99
 Table 4.18: Gen-Probe Genetic Testing Product Line 106
 Table 4.19: Prostate Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of
 Impact 112
 Table 4.20: Prostate Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked in Order of
 Impact 112
 Table 4.21: Summary of Strengths, Weaknesses, Opportunities and Threats of the Prostate Cancer Molecular Diagnostic Market 113
 Table 4.22: Worldwide CA 19-9 Sales, 2009-2019 116
 Table 4.23: U.S. CA 19-9 Sales, 2009-2019 116
 Table 4.24: Japan CA 19-9 Sales, 2009-2019 117
 Table 4.25: Europe CA 19-9 Sales, 2009-2019 117
 Table 4.26: Rest of the World CA 19-9 Sales, 2009-2019 118
 Table 4.27: CA 19-9 Levels in Management of Pancreatic Cancer 118
 Table 4.28: Worldwide CA 15-3 Sales, 2009-2019 121
 Table 4.29: U.S. CA 15-3 Sales, 2009-2019 122
 Table 4.30: Japan CA 15-3 Sales, 2009-2019 122
 Table 4.31: Europe CA 15-3 Sales, 2009-2019 123
 Table 4.32: Rest of the World CA 15-3 Sales, 2009-2019 123
 Table 4.33: TPA Marker Sensitivity 126
 Table 4.34: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: How to Interpret Test Results 127
 Table 4.35: Oncogene Science Biomarker Group Reagents 130
 Table 4.36: Worldwide CA-125 Sales, 2009-2019 133
 Table 4.37: U.S. CA-125 Sales, 2009-2019 134
 Table 4.38: Japan CA-125 Sales, 2009-2019 134
 Table 4.39: Europe CA-125 Sales, 2009-2019 135
 Table 4.40: Rest of the World CA-125 Sales, 2009-2019 135
 Table 4.41: Worldwide HVP Sales, 2009-2019 140
 Table 4.42: U.S. HVP Sales, 2009-2019 140
 Table 4.43: Japan HVP Sales, 2009-2019 141
 Table 4.44: Europe HVP Sales, 2009-2019 141
 Table 4.45: Rest of the World HVP Sales, 2009-2019 142
 Table 4.46: HCPCS Codes for Screening Pap Tests 143
 Table 4.47: HCPCS Codes for Screening Pap Tests 143
 Table 4.48: Number of Pap Smears Performed by Country 144
 Table 4.49: Lung Cancer Survival Rates 146
 Table 4.50: American Cancer Society Lung Cancer Facts 147
 Table 4.51: Predictive and Prognostic Rates 152
 Table 4.52: Tests Identifying Molecular Markers in Urine 157
 Table 4.53: Worldwide NMP22/BTA Sales, 2009-2019 158
 Table 4.54: U.S. NMP22/BTA Sales, 2009-2019 158
 Table 4.55: Japan NMP22/BTA Sales, 2009-2019 159
 Table 4.56: Europe NMP22/BTA Sales, 2009-2019 159
 Table 4.57: Rest of the World NMP22/BTA Sales, 2009-2019 160
 Table 4.58: Patient Category Applications 160
 Table 4.59: Worldwide Alpha-Fetal Protein (AFP) Sales, 2009- 2019 165
 Table 4.60: U.S. Alpha-Fetal Protein (AFP) Sales, 2009-2019 166
 Table 4.61: Japan Alpha-Fetal Protein (AFP) Sales, 2009-2019 166
 Table 4.62: Europe Alpha-Fetal Protein (AFP) Sales, 2009-2019 167
 Table 4.63: Rest of the World Alpha-Fetal Protein (AFP) Sales, 2009-2019 167
 Table 4.64: Key Oncology Diagnostic Tests, Roche, 2013 172
 Table 4.65: Potential Uses of Molecular Diagnostics in Cancer Management 179
 Table 4.66: Markers Frequently Used to Identify Adult Stem Cells in the Prostate, Breast and Intestine 185
 Table 4.67: MammaPrint: Key Features 191
 Table 6.1: Tumor Marker Tests 217
 Table 6.2: Tumor Diagnosis Immunoassays 218
 Table 6.3: Tumor Diagnosis Radioimmunoassays 218
 Table 6.4: PBM Product List 242
 Table 7.1: List and Discounted Prices for Abbott Tumor Marker Tests 252
 Table 8.1: CPT Codes for Tumor Markers 265
 Table 10.1: Categories of Oncogenes 283
 Table 1


List Of Figures

Figure 1.1: Medicines in Development in Cancer 15
Figure 4.1: Bowel Cancer including Anal Cancer: 2008 Estimates: World Age-Standardized Incidence Rates per 100,000 Population, World Regions 67
Figure 4.2: Percentage of Adults Aged 50-75 Years Who Reported Being Up-to-Date with Colorectal Test Screening, by State Behavioral Risk Factor Surveillance System in the U.S., 2010 71
Figure 4.3: Model of CRC Development 71
Figure 4.4: Progression of CRC Development 72
Figure 4.5: Prostate Cancer (C61): 2008 Estimates: World Age- Standardized Incidence Rates per 100,000 Population, Males, World Regions 81
Figure 4.6: Prostate Cancer (C61): 2008 Estimates: European Age-Standardized Incidence Rates per 100,000 Population, Males, EU27 Countries 82
Figure 4.7: Estimates for PCA3 Test Volume in U.S., 2005-2012 105
Figure 4.8: Pancreatic Cancer: 2008 Estimates: World Age- Standardized Incidence Rates per 100,000 Population, Male and Females, World Regions 115
Figure 4.9: Breast Cancer: 2008 Estimates: World Age- Standardized Incidence Rates per 100,000 Population, Females, World Regions 120
 Figure 4.10: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Equivocal Results with IHC 128
 Figure 4.11: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Results by FISH 129
 Figure 4.12: Ovarian Cancer: 2008 Estimates: European Age- Standardized Incidence Rates per 100,000 population, Females, EU27 Countries 132
 Figure 4.13: Cervical Cancer: 2008 Estimates: World Age- Standardized Incidence Rates per 100,000 Population, Females, World Regions 139
 Figure 4.14: Lung Cancer: 2008 Estimates: World Age- Standardized Incidence Rates per 100,000 Population, World Regions 145
 Figure 4.15: The BTA stat Test vs. Cytology 162


H. Lee Moffitt Cancer Center & Research Institute, Inc Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

H. Lee Moffitt Cancer Center & Research Institute, Inc Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies

USD 200View Report

Fred Hutchinson Cancer Research Center Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

Fred Hutchinson Cancer Research Center Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions,

USD 200View Report

Fox Chase Cancer Center Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

Fox Chase Cancer Center Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT

USD 200View Report

Global Cancer Diagnostics Device Sales Market Report 2016

Notes:Sales, means the sales volume of Cancer Diagnostics DeviceRevenue, means the sales value of Cancer Diagnostics DeviceThis report studies sales (consumption) of Cancer Diagnostics Device in Global market, especially in

USD 4000View Report

Global Cancer Diagnostics Device Market Research Report 2016

Notes:Production, means the output of Cancer Diagnostics DeviceRevenue, means the sales value of Cancer Diagnostics DeviceThis report studies Cancer Diagnostics Device in Global market, especially in North America, Europe, China,

USD 2900View Report

United States Transfusion Diagnostic Testing Analyzers Market Report 2016

Notes:Sales, means the sales volume of Transfusion Diagnostic Testing AnalyzersRevenue, means the sales value of Transfusion Diagnostic Testing AnalyzersThis report studies sales (consumption) of Transfusion Diagnostic Testing Analyzers in United

USD 3800View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 5500
  • 10 User Licence    $ 11000
  • Enterprise Wide Licence    $ 16500
$ 5500

Reports Details

Published Date : Jan 2016
No. of Pages :264
Country :Global
Category :Healthcare
Publisher :TriMark Publications, LLC
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment